Compare stocks

TELO vs ZBIO

Telomir Pharmaceuticals, Inc. Common Stock and Zenas BioPharma, Inc. Common Stock

Compare the businesses

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.

Open TELO dashboard ↗

Zenas BioPharma, Inc. Common Stock

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Open ZBIO dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗